CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

HOUSTON, June 11, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its lead product Berubicin for the treatment of malignant gliomas.

The release as fetched from its publisher. cnspharma.com ↗